No Data
No Data
No Data
No Data
No Data
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection
Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's National Medical Products Administration for its busulfan injection, according to the company's disclo
MT NewswiresApr 24 11:47
Huahai Pharmaceutical (600521.SH): Busulan injection obtained a drug registration certificate
Gelonghui, April 23 | Huahai Pharmaceutical (600521.SH) announced that the company recently received the “Drug Registration Certificate” for the Bexuan injection approved and issued by the State Drug Administration. Busulinan injection is suitable for use with cyclophosphamide as a pretreatment plan for hematopoietic progenitor cells of chronic myeloid leukemia before transplantation.
Gelonghui FinanceApr 23 17:58
Express News | The period of use of 11.5 million idle funds raised for temporary replenishment has been over 12 months. Huahai Pharmaceutical and the chairman of the board have been issued a warning letter by the Zhejiang Securities Regulatory Bureau
BreakingsApr 19 16:48
Express News | Huahai Pharmaceutical: The company and related personnel received a warning letter from the Zhejiang Securities Regulatory Bureau
BreakingsApr 19 16:41
Huahai Pharmaceutical (600521.SH) completed the repurchase of 7.023,600 shares at a cost of about 100 million yuan
Huahai Pharmaceutical (600521.SH) announced that on April 17, 2024, the company completed the repurchase and actually repurchased the public...
Zhitong FinanceApr 18 18:40
Investors Continue Waiting On Sidelines For Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)
It's not a stretch to say that Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) price-to-earnings (or "P/E") ratio of 27x right now seems quite "middle-of-the-road" compared to the market in
Simply Wall StApr 18 14:38
No Data
No Data